紫杉醇、奈达铂化疗序贯放疗用于晚期食管癌的临床效果观察

Paclitaxel and nedaplatin chemotherapy radiotherapy for advanced esophageal cancer clinical observation

目的紫杉醇、奈达铂化疗序贯放疗用于晚期食管癌的临床效果。方法选取2014年1月~2015年1月我院收治晚期食管癌患者80例,随机分为对照组和观察组,各40例,对照组予以单纯放疗治疗,观察组予以紫杉醇、奈达铂化疗序贯放疗,对比两组患者治疗效果及毒副反应情况。结果观察组近期治疗有效率为87.5%,对照组近期治疗有效率为60.0%,观察组的治疗有效率高于对照组,差异有统计学意义（P〈0.05）;观察组白细胞计数下降、血小板计数下降、恶性呕吐、肝功能损害及口腔黏膜炎的发生率分别为35.0%、22.5%、27.5%、7.5%、45.0%,对照组白细胞计数下降、血小板计数下降、恶性呕吐、肝功能损害及口腔黏膜炎的发生率分别为67.5%、55.0%、70.0%、35.0%、77.5%。观察组各种毒副反应发生率明显低于对照组,差异有统计学意义（P〈0.05）;一年后随访,观察组生存率为80.0%。对照组生存率为47.5%,观察组的生存率高于对照组（P〈0.05）。结论紫杉醇、奈达铂化疗序贯放疗用于晚期食管癌的临床效果显著,毒副反应少,值得临床推广。

Objective To explore paclitaxel and nedaplatin chemotherapy sequential radiotherapy for advanced esophageal cancer clinical effect.Methods Select January 2014 and 2015 January in our hospital were advanced esophageal cancer patients with 80 cases,and randomly divided into control group and observation group,each group of40 cases.The control group treated with radiotherapy alone in the treatment,the observation group were given paclitaxel,nedaplatin chemotherapy sequential therapy,compared two groups of treatment effect and side reaction.Results In the observation group of short-term effective rate was 87.5%,control group of the short-term effective rate was 60.0%, the treatment efficiency of observation group is higher than that of control group,the difference has statistical Significant（P 〈0.05）.In the observation group,the white blood cell count decreased,decreased platelet count,nausea and vomiting,liver function damage and oral mucositis incidence rate were 35.0% 、22.5% 、27.5% 、7.5% 、45.0%,the control group of white cell count decreased,platelet count decreased,nausea and vomiting,liver function damage and oral mucositis incidence were 67.5%,55.0%,70.0%,35.0%,77.5%.Observation group of toxic or adverse reaction occurred rate was significantly lower than that of control group,the difference is statistically significant（P〈0.05）;after one year follow-up observation group survival rate was 80.0%.The control group survival rate was 47.5%,the survival rate was higher than that of control group（P 〈0.05）.Conclusion Paclitaxel,nedaplatin chemotherapy sequential radiotherapy for significantly advanced esophageal cancer clinical effect,less adverse reaction,it is worth clinical promotion.